These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Crop Science faces ongoing challenges and litigation pressures, notably impacting overall group performance. Despite restructuring efforts, Bayer's financial outlook for 2025 remains weak, with ...

Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...

Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...